MIM
NTLA icon

Monashee Investment Management’s Intellia Therapeutics NTLA Stock Holding History

Monashee Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,000
Closed -$1.36M – 414
2020
Q4 		$1.36M Buy
+25,000
New +$908K 0.18% 141
2020
Q3 		– Sell
-110,000
Closed -$2.31M – 229
2020
Q2 		$2.31M Buy
+110,000
New +$1.87M 0.35% 91
2016
Q2 		– Hold
0
– – – 39

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Monashee Investment Management's NTLA Position: Q1 2021 in Review

Monashee Investment Management sold out of Intellia Therapeutics (NTLA) in Q1 2021, closing a stake of 25,000 shares — an estimated $1.36M sold.

Monashee Investment Management first reported a position in NTLA in Q2 2020 and held it in 2 quarters. The position peaked at $2.31M in Q2 2020. 260 funds tracked by Wall St. Rank hold NTLA as of Q1 2021.

  • Monashee Investment Management reported no remaining Intellia Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Monashee Investment Management sold 25,000 Intellia Therapeutics shares in Q1 2021, an estimated $1.36M.
  • Monashee Investment Management first reported a position in Intellia Therapeutics in Q2 2020 and held it in 2 quarters.
  • Monashee Investment Management's Intellia Therapeutics position peaked at $2.31M in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2021.

Based on Monashee Investment Management's 13F filing for Q1 2021, filed 14 May 2021.